Adverse effects of direct acting antiviral-based regimens in chronic hepatitis C patients: a Brazilian experience.

about

Restoring Inflammatory Mediator Balance after Sofosbuvir-Induced Viral Clearance in Patients with Chronic Hepatitis C.

P2860

Q55436171-FEE70F37-C510-4F85-A042-155DDF71141A

P2860

Adverse effects of direct acting antiviral-based regimens in chronic hepatitis C patients: a Brazilian experience.

Item

http://www.wikidata.org/entity/Q48110717

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Adverse effects of direct acti ...... ients: a Brazilian experience.

@en

Adverse effects of direct acti ...... ients: a Brazilian experience.

@nl

type

Item

label

Adverse effects of direct acti ...... ients: a Brazilian experience.

@en

Adverse effects of direct acti ...... ients: a Brazilian experience.

@nl

prefLabel

Adverse effects of direct acti ...... ients: a Brazilian experience.

@en

Adverse effects of direct acti ...... ients: a Brazilian experience.

@nl

P1476

Adverse effects of direct acti ...... ients: a Brazilian experience.

@en

P2093

Analúcia Rampazzo Xavier

http://www.w3.org/2001/XMLSchema#string

Camila de Morais Salviato

http://www.w3.org/2001/XMLSchema#string

Eliane Bordalo Cathalá Esberard

http://www.w3.org/2001/XMLSchema#string

Geórgia do Nascimento Saraiva

http://www.w3.org/2001/XMLSchema#string

Natalia Fonseca do Rosário

http://www.w3.org/2001/XMLSchema#string

Thalia Medeiros

http://www.w3.org/2001/XMLSchema#string

P2860

Efficacy of Second Generation Direct-Acting Antiviral Agents for Treatment Naïve Hepatitis C Genotype 1: A Systematic Review and Network Meta-Analysis

Hepatitis C virus infection increases risk of developing end-stage renal disease using competing risk analysis.

Feasibility of pegylated interferon and ribavirin in hepatitis C-related cirrhosis with neutropenia or thrombocytopenia.

[Incidence, management and costs of adverse effects in chronic hepatitis C patients on triple therapy with telaprevir or boceprevir: first 12 weeks of treatment].

Comparison of adverse effects related to pegylated interferon-based therapy for patients with chronic hepatitis B and chronic hepatitis C in Taiwan.

Hepatitis C virus itself is a causal risk factor for chronic kidney disease beyond traditional risk factors: a 6-year nationwide cohort study across Taiwan

Retreatment of Chronic Hepatitis C Infection with Telaprevir: Preliminary Results in Turkey.

Re-treatment of chronic hepatitis C virus genotype 1 infection after relapse: an open-label pilot study.

Second-generation direct-acting-antiviral hepatitis C virus treatment: Efficacy, safety, and predictors of SVR12.

Modeling Ribavirin-Induced Anemia in Patients with Chronic Hepatitis C Virus

P2888

s11096-017-0552-1

P304

1304-1311

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S11096-017-0552-1

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Jorge Reis Almeida

Andrea Alice Silva

P577

2017-10-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29079938

http://www.w3.org/2001/XMLSchema#string

Adverse effects of direct acting antiviral-based regimens in chronic hepatitis C patients: a Brazilian experience.

about

P2860

P2860

Adverse effects of direct acting antiviral-based regimens in chronic hepatitis C patients: a Brazilian experience.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P698